Analysts Set Perspective Therapeutics, Inc. (NYSE:CATX) Target Price at $14.44

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has been given an average recommendation of "Buy" by the twelve research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $13.22.

CATX has been the topic of a number of research reports. Royal Bank of Canada cut their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating on the stock in a research note on Thursday, March 27th. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Perspective Therapeutics in a report on Monday, March 31st. Scotiabank began coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price for the company. Brookline Capital Management upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Wedbush reiterated an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Wednesday, March 26th.

Perspective Therapeutics Stock Performance

NYSE:CATX traded down $0.09 during trading hours on Friday, hitting $1.71. The company had a trading volume of 806,686 shares, compared to its average volume of 1,016,178. Perspective Therapeutics has a 52 week low of $1.62 and a 52 week high of $19.05. The stock has a 50-day moving average price of $2.65 and a 200 day moving average price of $5.67.

Insider Activity at Perspective Therapeutics

In other news, Director Robert F. Williamson III purchased 38,145 shares of Perspective Therapeutics stock in a transaction that occurred on Monday, March 31st. The stock was bought at an average price of $2.14 per share, with a total value of $81,630.30. Following the completion of the transaction, the director now directly owns 108,982 shares of the company's stock, valued at approximately $233,221.48. The trade was a 53.85 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Johan M. Spoor acquired 22,026 shares of the stock in a transaction that occurred on Friday, March 28th. The stock was acquired at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the transaction, the chief executive officer now directly owns 59,383 shares in the company, valued at $133,017.92. This represents a 58.96 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 115,696 shares of company stock valued at $256,344. 3.52% of the stock is owned by insiders.

Institutional Trading of Perspective Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Y Intercept Hong Kong Ltd purchased a new stake in shares of Perspective Therapeutics during the fourth quarter valued at $33,000. Aigen Investment Management LP purchased a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $34,000. National Bank of Canada FI grew its stake in shares of Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after acquiring an additional 10,998 shares during the period. ProShare Advisors LLC grew its stake in shares of Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after acquiring an additional 5,011 shares during the period. Finally, Vontobel Holding Ltd. purchased a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $51,000. Institutional investors own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.